Cagrilintide
Also called cagri, AM833
Not a GLP-1 at all - an amylin analogue, which is a different hormone entirely.
Tested in large, properly controlled human trials. The ranges below are drawn from that trial data alongside what the community reports using.
- Belly fat / contouring
- Fat loss & metabolic
The quick answer
Not a GLP-1 at all - an amylin analogue, which is a different hormone entirely. Amylin works on fullness and how quickly the stomach empties, by a separate route from GLP-1. That is why it is almost always talked about alongside semaglutide rather than instead of it: two different signals, same problem.
What it is not
Not approved anywhere on its own. The phase 3 work is on the combination.
Why people use it
Fullness and slowed gastric emptying. In the combination trials the pairing outperformed either alone, which is the whole case for it.
What people report using
These are ranges other people have reported running. They are here so you can see what has actually been done — they are not medical advice and not a recommendation for you.
- How often
- Once weekly
- Route
- subcutaneous
- Evidence for this
- Large human trials
Mix the 10mg vial with 2ml of bacteriostatic water. That gives 5mg/ml, so one unit on a U-100 syringe is 0.05mg and every dose on the ladder lands on a whole unit.
Work out your own units on the reconstitution calculator — the most common serious mistake in this area is arithmetic, not chemistry.
What to expect, and when
- First thing people notice
- Weeks 1–2 (at the table)
- When it gets real
- Weeks 4–6 (scale movement)
- Where it peaks
- Months 6–16 (still climbing)
- Patience needed
- High - slow and quiet by nature
- Days 1–7Nothing dramatic - and that is expected
Most people feel very little in the first week, and that is normal rather than a sign it is not working. The opening step is there to build tolerance, not to do the work. Some notice mild queasiness in the day or two after the shot; some notice tiredness instead, which is the effect real-world users report most and the trials mention least. If you are watching for appetite to disappear, you will conclude nothing is happening. Watch the plate instead.
- Weeks 1–2Meals start ending sooner
The first real sign is usually leaving food behind without having decided to. Portions that used to be right start feeling like slightly too much. Evening grazing is often the first habit to fall away. Hunger before meals is unchanged - you sit down just as hungry, you just stop earlier.
- Weeks 3–6Stepping up · the step-up window
This is the working part of the schedule and the least comfortable. Nausea clusters in the days after each step up and then settles. The phase 3 trial is reassuring here - gut effects were mostly mild to moderate and improved over time, and only about 1% of people stopped because of nausea. Injection-site redness or a small lump is more common with this than with a GLP-1 (17% against 2.6% on semaglutide), so rotate your sites. If a week was hard, hold that step rather than climbing on schedule. Nobody has ever been harmed by taking an extra week.
- Weeks 6–12At the full amount · the scale follows
Reaching the studied amount takes as long as six weeks of stepping, and the effect keeps building for weeks after you get there. This is where most people first see the scale move consistently rather than in fits. Fullness now lasts across the whole week instead of fading by day five, and the step-up nausea should be behind you.
- Months 3–6Steady loss - and easy to underrate here
This is where the 26-week trials stopped and reported 6% to 10.8%. It is real progress but it is not the finished picture, and it is the point at which someone comparing notes with a friend on a GLP-1 is most likely to feel short-changed. The loss is unrushed and undramatic, which is exactly why the people who stay on it tend to stay on it comfortably.
- Months 6–16The full picture · 11.8% average
The phase 3 REDEFINE 1 trial ran 68 weeks and this is where it landed: 11.8% average weight loss on cagrilintide alone, against 2.3% on placebo, with 31.6% of people losing 15% or more of their body weight. Out of 3,417 participants. Most of the write-ups you will find online still quote the shorter 26-week number, which sells it short. Paired with a GLP-1 the figures are considerably higher, but pairing is a conversation with us, not a ladder we publish.
This is not a GLP-1 and it will not feel like one. There is no moment where the food noise goes silent - appetite stays, and the change shows up at the end of a meal instead of the start. Almost everyone who quits early quits because they spent two weeks waiting for a feeling that was never going to arrive. Judge it by portion size and by how long you go afterwards, not by how much you want dinner. Two other things to hold in mind: people respond to this very differently, so feeling nothing at first is common and so is being hit hard, and fatigue rather than nausea is what most often makes someone stop. And give it longer than you think - the 26-week trials showed 6-10%, the 68-week trial showed 11.8%. This one is still working long after most people have made up their mind about it.
Side effects, and what people do about them
Nausea is the main one from the trials, and it tracks the steps rather than the compound - it turns up in the days after a step up and settles. In the phase 3 trial the gut effects were mostly mild to moderate and improved over time, and only about 1% of people stopped because of nausea. If a week was rough, hold that step rather than climbing. If it is not settling, back down one.
Fatigue is the one to actually watch for, and you will not find it emphasized in the trial data. In real-world reports it is the most common reason people stop - described as being drained, flattened, no energy for a few days after the shot. If that is you, it is a known effect and not something you are imagining. Tell us rather than pushing through it.
Injection-site reactions are more common with this than with a GLP-1 - 17% against 2.6% on semaglutide in the same trial. Usually redness or a small lump. Rotate your sites and give each one a rest.
Response varies more than with most things we carry. Some people feel almost nothing for weeks; others are affected strongly and quickly. If you find yourself genuinely unable to eat rather than simply eating less, that is too much - stop and message us the same day. Not eating is not the goal and it will cost you muscle.
Go deeper
Open these only if you want them.
How it actually works
Long-acting amylin analogue.
What people report, in full
What people using cagrilintide on its own describe does not line up neatly with the trial data, and it is worth knowing before you start.
Response is split, and split widely. A fair number of people report feeling nothing at all, three weeks in. Others are hit hard and fast, describing days where a couple of bites was all they could manage. Same compound, similar amounts. There is no way to know in advance which one you will be, and that is the best argument there is for starting low and moving up slowly rather than starting where the trial did.
Fatigue is the thing the trials do not prepare you for. It comes up over and over, in separate reports from people with no connection to each other - drained, wiped out, no energy for days after the shot - and for several of them it was the reason they stopped, not nausea. It is the most consistent theme in the whole community record and it is barely visible in the published data.
The fullness-not-appetite distinction is confirmed by the people using it, and it cuts both ways. One person described being full faster while the food noise stayed exactly the same, and still being able to eat past it. If your problem is portion size, that is the compound doing its job. If your problem is thinking about food all day, this may not touch it.
The amounts people actually use run below the trial's, consistently and in the same direction. We are not publishing those numbers, because we have not counted them yet and a ladder with no number of people behind it is just a rumour in a nicer font. If you have seen them, bring them to us before you draw anything up.
It is often used as a bridge. A recurring pattern is people who have stalled on retatrutide, or who want a break from a GLP-1, running cagrilintide on its own to hold their weight in the meantime. Those reports are mostly positive. One caution from the same record: for some people the strong early effect fades and does not return at the same amount.
Sources and review
https://pubmed.ncbi.nlm.nih.gov/34798060/
https://pubmed.ncbi.nlm.nih.gov/40544433/
Last reviewed 2026-09-08.
People also look at
Still not sure?
Ask it the way you would ask a person. Follow-up questions are the point — it remembers what you already said.
Ask about Cagrilintide